论文部分内容阅读
目的:评价美罗培南和亚胺培南治疗急性白细胞减少期并发肺部感染的成本-效果。方法:采用回顾性方法,对67例分别采用美罗培南和亚胺培南治疗急性白细胞减少期并发肺部感染的效果进行成本-效果分析。结果:美罗培南组与亚胺培南组的成本分别为3 639.00、6 664.00元;有效率分别为85.29%、90.91%(P>0.05);成本-效果比分别为4 266.62、7 331.21,亚胺培南组相对于美罗培南组的增量成本-效果比为53 839.86。结论:美罗培南治疗急性白血病粒细胞减少期并发肺部感染有明显的药物经济学优势。
OBJECTIVE: To evaluate the cost-effectiveness of meropenem and imipenem in the treatment of acute leukopenia complicated with pulmonary infections. Methods: A retrospective analysis of 67 patients with meropenem and imipenem, respectively, for the treatment of acute leukopenia with pulmonary infection was performed cost-effectiveness analysis. Results: The costs of meropenem and imipenem were 3639.00 and 6664.00 yuan respectively, the effective rates were 85.29% and 90.91% respectively (P> 0.05), and the cost-effectiveness ratios were 4 266.62 and 7 331.21 respectively The incremental cost-effectiveness ratio of aminepenem to meropenem was 53 839.86. Conclusion: Meropenem has obvious pharmacological and economic advantages in the treatment of acute myeloid leukopenia with pulmonary infection.